date,title,source
Oct-25-18,Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results,GlobeNewswire
Nov-01-18,Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates,GlobeNewswire
Nov-05-18,Todays Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Titan Pharmaceuticals,ACCESSWIRE
Nov-08-18,Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting,GlobeNewswire
Nov-09-18,Edited Transcript of CNAT earnings conference call or presentation 1-Nov-18 8:30pm GMT,Thomson Reuters StreetEvents
Nov-14-18,Do Options Traders Know Something About Conatus (CNAT) Stock We Don't?,Zacks
Nov-16-18,When Will Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Become Profitable?,Simply Wall St.
Nov-16-18,"Investor Expectations to Drive Momentum within 2U, Broadwind Energy, Nuverra Environmental Solutions, Ability, ContraFect, and Conatus Pharmaceuticals  Discovering Underlying Factors of Influence",GlobeNewswire
Dec-06-18,Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study,Zacks
Dec-06-18,Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint,MarketWatch
Dec-06-18,Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis,ACCESSWIRE
Dec-07-18,"The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut",Benzinga
Dec-12-18,"Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate",Zacks
Dec-13-18,"The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis",Zacks
Dec-28-18,Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan,Zacks
Jan-28-19,"Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials",GlobeNewswire
Jan-29-19,Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?,Zacks
Jan-30-19,Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals,ACCESSWIRE
Feb-12-19,Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis,GlobeNewswire
Feb-13-19,Conatus (CNAT) Completes Enrollment in Phase II NASH Study,Zacks
Feb-25-19,Is Conatus Pharmaceuticals Inc.s (NASDAQ:CNAT) CEO Pay Justified?,Simply Wall St.
Mar-01-19,Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results,GlobeNewswire
Mar-08-19,Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates,GlobeNewswire
Mar-11-19,Edited Transcript of CNAT earnings conference call or presentation 8-Mar-19 9:30pm GMT,Thomson Reuters StreetEvents
Mar-11-19,"Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus",Zacks
Mar-13-19,Implied Volatility Surging for Conatus (CNAT) Stock Options,Zacks
Mar-13-19,Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension,GlobeNewswire
Mar-14-19,Edited Transcript of CNAT earnings conference call or presentation 8-Mar-19 9:30pm GMT,Thomson Reuters StreetEvents
Mar-20-19,Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan,Zacks
Mar-21-19,Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis,GlobeNewswire
Mar-22-19,Conatus (CNAT) Declines on Failure of NASH Fibrosis Study,Zacks
Mar-22-19,Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo,Benzinga
Mar-27-19,"Biotech Stock Roundup: BIIB &amp; CNAT Crash on Study Failures, LXRX Gets CRL",Zacks
Apr-02-19,Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference,GlobeNewswire
Apr-15-19,Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension,GlobeNewswire
Apr-24-19,Conatus Pharmaceuticals (CNAT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release,Zacks
Apr-30-19,"Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis",GlobeNewswire
May-02-19,"Conatus Pharmaceuticals (CNAT) Reports Q1 Loss, Lags Revenue Estimates",Zacks
May-02-19,Conatus: 1Q Earnings Snapshot,Associated Press
May-06-19,"Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1",Zacks
